Knight Therapeutics Reports Third Quarter 2025 Results
Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a pan-Americ
(Financial Post, 2025-11-06T12:34:39Z)